Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia

Sen, Sagnik; Rajan, Renu P; Damodaran, Sourav; Arumugam, Karthik Kumar; Kannan, Naresh Babu; Ramasamy, Kim

doi:10.1007/s00417-020-05007-w

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of proliferative Type 2 MacTel with anti–vascular endothelial growth factor agents shows improvement, but recurrence after cessation of therapy is common and the risk of further atrophy with repeated injections. 10 Feeder vessel laser photocoagulation achieved regression of the neovascular complex by noting reduction in the height of central foveal thickness and no recurrence of the disease or need for anti–vascular endothelial growth factor therapy up to 6-month follow-up visits. Also, there was improvement in the visual acuity at the final follow-up visit.…”

Section: Discussionmentioning

confidence: 92%

Direct Laser Photocoagulation to the Dilated Right-Angled Vessel in the Management of Proliferative Type 2 Macular Telangiectasia

Reddy

Venkatesh

Jayadev

et al. 2023

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

Purpose: To report a case of proliferative Type 2 macular telangiectasia treated successfully with direct laser photocoagulation to the right-angled vessel.Methods: Descriptive case report.Case Description: A 61-year-old man, with no past medical history, was diagnosed and treated previously elsewhere for bilateral proliferative Type 2 macular telangiectasia. He complained of recent onset decrease in vision in his right eye for last 2 months. Right eye visual acuity was counting fingers at 3 m and left eye was 6/18. Fundus examination showed proliferative Type 2 macular telangiectasia in both eyes with active neovascular complex in the right eye. Direct thermal laser photocoagulation to the tips of the rightangled vessels with single-spot PASCAL Synthesis (Topcon Medical Laser System) at 532 nm wavelength was done. After laser, reduction in the hyporeflective space height was noted on optical coherence tomography. No additional intravitreal anti-vascular endothelial growth factor injections were required. At the last 6-months follow-up visit, visual acuity improved to 6/36, N18 in the right eye.Conclusion: Direct laser photocoagulation to the right-angled vessel can be considered as possible treatment option for proliferative Type 2 macular telangiectasia, especially in patients nonresponsive to anti-vascular endothelial growth factor therapy. However, longterm follow-ups are required to see whether it is possible to maintain the efficacy.

show abstract

Section: Discussionmentioning

confidence: 92%

Direct Laser Photocoagulation to the Dilated Right-Angled Vessel in the Management of Proliferative Type 2 Macular Telangiectasia

Reddy

Venkatesh

Jayadev

et al. 2023

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

show abstract

“…A previous study by Tzaridis et al highlighted that OCTA identifies neovascularization in patients with MacTel earlier than OCT B-scans, thereby allowing for earlier treatment initiation and improving functional outcomes [ 35 ]. Numerous studies have found anti-VEGF agents to be successful treatments for proliferative MacTel based on their ability to stabilize or even improve BCVA [ 36 , 37 ]. Figure 3 demonstrates the use of OCTA to track SRNV in response to treatment with bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2

Moir

Amin

Khanna

et al. 2022

IJMS

View full text Add to dashboard Cite

Macular telangiectasia Type 2 (MacTel) is a bilateral acquired retinal disease characterized by both vascular changes and atrophy of the retina. The purpose of this case series is to highlight the use of optical coherence tomography angiography (OCTA) as a non-invasive imaging modality to distinguish atypical MacTel from other macular conditions with similar presentations. We performed a retrospective review of patients referred to our academic retinal practice with unconfirmed or misdiagnosed MacTel between July 2017 and July 2021. Patients’ OCTA imaging findings were reviewed to guide the appropriate diagnosis and management of atypical MacTel. Fifteen eyes from eight patients were included in this study. Six patients were referred with previous diagnoses of either full-thickness macular hole, lamellar hole, vitreomacular traction (VMT), postoperative cystoid macular edema (CME), or diabetic macular edema (DME). Two patients were referred to us to confirm the diagnosis of MacTel. OCTA revealed telangiectatic vessels in the temporal parafovea of all 15 eyes. OCTA also highlighted previously undiagnosed subretinal neovascularization (SRNV) in seven eyes. OCTA imaging is a valuable imaging modality to distinguish MacTel from other macular conditions, whose treatment courses vary substantially. Due to its ease of use, it holds immense potential in the future as treatments for non-proliferative MacTel emerge.

show abstract

The preproliferative stage in type 2 macular telangiectasia (MacTel type 2)

Venkatesh

Reddy

Mishra

et al. 2021

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia

Cited by 4 publications

References 25 publications

Direct Laser Photocoagulation to the Dilated Right-Angled Vessel in the Management of Proliferative Type 2 Macular Telangiectasia

Direct Laser Photocoagulation to the Dilated Right-Angled Vessel in the Management of Proliferative Type 2 Macular Telangiectasia

Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2

The preproliferative stage in type 2 macular telangiectasia (MacTel type 2)

Contact Info

Product

Resources

About